CreativeOne Wealth LLC Takes Position in Sanofi (NASDAQ:SNY)

CreativeOne Wealth LLC acquired a new position in Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,769 shares of the company's stock, valued at approximately $423,000.

Several other institutional investors and hedge funds have also recently modified their holdings of SNY. Arkadios Wealth Advisors grew its position in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after buying an additional 751 shares during the period. Geode Capital Management LLC boosted its position in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. increased its position in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after buying an additional 399,301 shares in the last quarter. Kentucky Trust Co purchased a new position in Sanofi during the fourth quarter valued at $436,000. Finally, World Investment Advisors LLC grew its stake in shares of Sanofi by 1,020.5% in the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after acquiring an additional 44,108 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY stock traded up $0.52 during trading on Thursday, reaching $53.54. The stock had a trading volume of 4,135,909 shares, compared to its average volume of 2,373,551. The firm has a market cap of $135.26 billion, a PE ratio of 21.50, a PEG ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock's 50 day moving average is $54.58 and its two-hundred day moving average is $52.12. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.87 by $0.07. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a $2.0369 dividend. This represents a dividend yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's dividend payout ratio is 64.26%.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent analyst reports. BNP Paribas began coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.